C57bl 6 ly5

CB17-SCID and C57BL/6-Ly5.1 mice of 6-8 weeks old were purchased from Charles River (France and Germany, respectively). For imaging and biodistribution experiments, we used both the immunodeficient THP-1 xenograft model and the immunocompetent syngeneic C1498 mouse model. For the THP-1 xenografts, CB17-SCID mice were inoculated subcutaneously in the right flank with five million THP-1 cells that were diluted 1:1 with Matrigel (Corning, New York, USA). Tumor inoculation was performed under 2.5% isoflurane anaesthesia and subcutaneous tumor growth was allowed to a size of 250 ± 50 mm³. For the syngeneic C1498 mouse model, C57BL/6-Ly5.1 mice were inoculated intravenously with one million lentivirally transduced AXL^high C1498 cells under 2.5% isoflurane anaesthesia. C1498 mice were assessed daily for signs of leukemic disease (e.g., paralysis, weight loss). Prior to imaging, mice were anesthetized with 18.75 mg/kg of ketamine hydrochloride and 0.5 mg/kg of medetomidine hydrochloride. All animal experiments and housing conditions were approved by the Ethical Committee for Use of Laboratory Animals of the Vrije Universiteit Brussel and executed in accordance with the European guidelines for animal experimentation (License Agreement: LA 1230281, Files No.: 20-281-3, 21-281-2, 22-281-4, 23-281-1 and 23-281-4).

Tissue extraction for transcriptome studies and the in vivo shRNA screen were performed in Cold Spring Harbor Laboratories (NY, USA). RNAseq libraries for transcriptomic assembly and differential expression were prepared from female C57BL/6 (6–12 weeks old) purchased from Charles River (Wilmington MA). For the in vivo shRNA screen, female B6.SJL-Ptprc^a/BoAiTac (also known as LY5.1, 8–12 weeks old) were purchased from Taconic (Hudson, NY). All these experiments were approved by the Cold Spring Harbor Animal Care and Use Committee.
Bone marrow transplantations of modified HSCs and subsequent analysis of peripheral blood from these mice were performed at the Cancer Research UK Cambridge Institute (Cambridge, UK). C57BL6J (6–12 weeks old) were purchased from Charles River (Kent, England). C57BL/6-LY5.1 females were purchased from Charles River (Kent, England) and used at 9–12 weeks old. These animal procedures were conducted in accordance with project and personal licenses issued under the United Kingdom Animals (Scientific Procedures) Act, 1986.

All mice used were on a C57BL/6 background and bred in dedicated animal facilities of the Institut Pasteur. Actb^ECFP, Ccr9^−/−, Rorc^GFP, Il22^TdT and Ncr1^GFP mice were provided by P. Bousso, I. Prinz, G. Eberl, S. Durum and O. Mandelboim, respectively. C57BL/6 and C57BL/6 Ly5.1 mice were purchased from the Charles River Laboratories. All experiments were performed on 8–14-week-old male and female animals, except for experiments on bone marrow chimeric mice which involved 16-week-old males at the time of the analysis. All experiments involving mice were performed according to guidelines issued by the Institut Pasteur Ethics Committee and were approved by the French Ministry of Research (project nos. DHA170001, CETEA 2013-033 and CETEA 17500).

Dectin-1^−/− and MyD88^−/− mice were purchased from The Jackson Laboratory; TLR2^−/− were provided by Shizuo Akira (Osaka University, Osaka, Japan). All knockout mice have a C57BL/6 background and were maintained at the animal production service facilities (SCSIE, University of Valencia). Wild-type C57BL/6 mice (Envigo) were used as controls; wild-type CD45.1-positive allotype mice (B6.SJL-Ptprc^a Pepc^b/BoyCrl strain, also known as C57BL/6-Ly5.1 [Charles River Laboratories]) and the transgenic mice (B6.Cg-Tg[CAG-DsRed*MST]1Nagy/J strain, also known as DsRed.T3 [The Jackson Laboratory]) were used for in vivo transplantation assays and/or for the in vitro coculture assays. Experiments were conducted with 8- to 12-week-old mice (regardless of sex). Experiments were approved by the Committee on the Ethics of Animal Experiments of the University of Valencia (permit numbers 2017/VSC/PEA/00207 and 2019/VSC/PEA/0030) and performed according to Spanish law under Reales Decretos 1201/2005 and 53/2013. All efforts were made to minimize suffering.